1. Interaction of D₃ preferring agonist (−)-N ⁶-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N ⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D_2L, D_2S, and D₃ receptors: potent stimulation of mitogen-activated protein kinases and G protein-coupled inward rectifier potassium channels

   • Eldo V. Kuzhikandathil
   • Samantha Cote
   • Aloke K. Dutta

   Original Article 20 November 2012 Pages: 97 - 105

   

2. Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia

   • Pierre Sokoloff
   • Ludovic Leriche
   • René Pumain

   Original Article Open access 22 September 2012 Pages: 107 - 124

   

3. Pergolide block of the cloned Kv1.5 potassium channels

   • Imju Jeong
   • Bok Hee Choi
   • Sang June Hahn

   Original Article 05 July 2012 Pages: 125 - 133

   

4. Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications

   • Jan-Peter van Wieringen
   • Jan Booij
   • Martin C. Michel

   Review 09 December 2012 Pages: 135 - 154

   

5. Dopamine D₃ receptor antagonism—still a therapeutic option for the treatment of schizophrenia

   • Gerhard Gross
   • Karsten Wicke
   • Karla U. Drescher

   Review 06 November 2012 Pages: 155 - 166

6. Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders

   • Christian Heidbreder

   Review 28 October 2012 Pages: 167 - 176